Nothing Special   »   [go: up one dir, main page]

JOP20200022A1 - مركبات حلقية لولبية وطرق تصنيعها واستخدامها - Google Patents

مركبات حلقية لولبية وطرق تصنيعها واستخدامها

Info

Publication number
JOP20200022A1
JOP20200022A1 JOP/2020/0022A JOP20200022A JOP20200022A1 JO P20200022 A1 JOP20200022 A1 JO P20200022A1 JO P20200022 A JOP20200022 A JO P20200022A JO P20200022 A1 JOP20200022 A1 JO P20200022A1
Authority
JO
Jordan
Prior art keywords
making
methods
same
compounds
spirocycle
Prior art date
Application number
JOP/2020/0022A
Other languages
English (en)
Inventor
Cheryl A Grice
Olivia D Weber
Michael B Shaghafi
Daniel J Buzard
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of JOP20200022A1 publication Critical patent/JOP20200022A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

غير متوفر
JOP/2020/0022A 2017-08-29 2018-08-28 مركبات حلقية لولبية وطرق تصنيعها واستخدامها JOP20200022A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762551714P 2017-08-29 2017-08-29
PCT/US2018/048388 WO2019046330A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
JOP20200022A1 true JOP20200022A1 (ar) 2020-02-02

Family

ID=65526036

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0022A JOP20200022A1 (ar) 2017-08-29 2018-08-28 مركبات حلقية لولبية وطرق تصنيعها واستخدامها

Country Status (24)

Country Link
US (1) US11161856B2 (ar)
EP (1) EP3675848B1 (ar)
JP (1) JP7177825B2 (ar)
KR (1) KR20200046053A (ar)
CN (1) CN111032034B (ar)
AU (1) AU2018326497A1 (ar)
BR (1) BR112020003946A2 (ar)
CA (1) CA3072926A1 (ar)
CL (1) CL2020000463A1 (ar)
CO (1) CO2020001715A2 (ar)
CR (1) CR20200088A (ar)
DO (1) DOP2020000040A (ar)
EA (1) EA202090296A1 (ar)
EC (1) ECSP20013332A (ar)
ES (1) ES2914363T3 (ar)
IL (1) IL272578A (ar)
JO (1) JOP20200022A1 (ar)
MA (1) MA50045A (ar)
MX (1) MX2020002254A (ar)
PE (1) PE20200665A1 (ar)
PH (1) PH12020500371A1 (ar)
RU (1) RU2020107039A (ar)
SG (1) SG11202000984YA (ar)
WO (1) WO2019046330A1 (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2800565B1 (en) 2012-01-06 2020-03-25 Lundbeck La Jolla Research Center, Inc. Carbamate compounds and methods of making and using same
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
ES2892952T3 (es) 2016-09-19 2022-02-07 H Lundbeck As Carbamatos de piperazina como moduladores del MAGL y/o ABHD6 y su uso
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20200022A1 (ar) 2017-08-29 2020-02-02 Lundbeck La Jolla Research Center Inc مركبات حلقية لولبية وطرق تصنيعها واستخدامها
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
CN112088001A (zh) 2018-05-15 2020-12-15 隆德贝克拉荷亚研究中心有限公司 Magl抑制剂
CN111505410B (zh) * 2020-04-02 2022-07-29 矽力杰半导体技术(杭州)有限公司 调光模式检测电路、方法和无调光检测电路及照明系统
IL297470A (en) 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
KR20230142745A (ko) 2021-01-29 2023-10-11 세딜라 테라퓨틱스, 인크. Cdk2 억제제 및 그의 사용 방법
WO2022272106A1 (en) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
AU2023264787A1 (en) * 2022-05-04 2024-10-31 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0207952A (pt) 2001-03-07 2004-07-27 Pfizer Prod Inc Moduladores da atividade de receptores de quimiocina
JPWO2008023720A1 (ja) * 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CA2778484C (en) 2009-10-23 2018-07-31 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US9108937B2 (en) 2010-03-04 2015-08-18 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
EP2800565B1 (en) 2012-01-06 2020-03-25 Lundbeck La Jolla Research Center, Inc. Carbamate compounds and methods of making and using same
UA116547C2 (uk) 2012-09-25 2018-04-10 Ф. Хоффманн-Ля Рош Аг Біциклічні похідні
WO2015003002A1 (en) * 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
ES2878041T3 (es) 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
GEP20207105B (en) 2015-07-31 2020-05-11 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
US10519134B2 (en) 2015-11-20 2019-12-31 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
JOP20200022A1 (ar) 2017-08-29 2020-02-02 Lundbeck La Jolla Research Center Inc مركبات حلقية لولبية وطرق تصنيعها واستخدامها

Also Published As

Publication number Publication date
EP3675848A4 (en) 2021-03-10
CO2020001715A2 (es) 2020-02-28
AU2018326497A1 (en) 2020-02-20
ES2914363T3 (es) 2022-06-09
IL272578A (en) 2020-03-31
CN111032034A (zh) 2020-04-17
KR20200046053A (ko) 2020-05-06
MA50045A (fr) 2020-07-08
EA202090296A1 (ru) 2020-08-03
US11161856B2 (en) 2021-11-02
RU2020107039A (ru) 2021-09-30
CR20200088A (es) 2020-04-08
JP7177825B2 (ja) 2022-11-24
US20210214375A1 (en) 2021-07-15
BR112020003946A2 (pt) 2020-09-08
PH12020500371A1 (en) 2020-12-07
EP3675848A1 (en) 2020-07-08
EP3675848B1 (en) 2022-03-23
MX2020002254A (es) 2020-07-20
JP2020532547A (ja) 2020-11-12
WO2019046330A1 (en) 2019-03-07
DOP2020000040A (es) 2020-08-31
PE20200665A1 (es) 2020-06-11
CA3072926A1 (en) 2019-03-07
SG11202000984YA (en) 2020-03-30
ECSP20013332A (es) 2020-04-22
CN111032034B (zh) 2023-05-02
CL2020000463A1 (es) 2020-07-10

Similar Documents

Publication Publication Date Title
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
PH12019502646A1 (en) Pyrazole magl inhibitors
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
PH12019501079A1 (en) Magl inhibitors
PH12019501097A1 (en) Magl inhibitors
GB2541571A (en) Pharmaceutical compositions
WO2015179559A3 (en) Pyrazole compounds and methods of making and using same
PH12019501102A1 (en) Magl inhibitors
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX2017012342A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades,.
MX2017017119A (es) Formulacion de alta concentracion.
WO2018211324A8 (en) Prodrugs for the treatment of disease
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy